Annual Report 2023

The road ahead

Read more about our strategy and business idea


Investor relations

Dicot Pharma develops LIB-01 into a new potency drug that aims to become the first choice globally for the treatment of erectile dysfunction and premature ejaculation.

LIB-01 is in the clinical development phase, where a clinical phase 1 study was completed with very good results in Q2 2024. A phase 2a study is planned to start in the second half of 2024.

Development is intended to be carried out under own auspices up to and including clinical phase 2a and then together with major pharmaceutical companies to introduce LIB-01 to the world market.

Dicot Pharma's share is listed on Spotlight Stock Market and the company has approximately 5,700 shareholders.

The global market for treating sexual dysfunctions is annually worth more than 80 billion SEK as the underlying causes increase and the proportion of elderly increases

Today's potency drugs were launched over twenty years ago and have limitations

Up to 35% of men with erection problems do not respond to current treatments. LIB-01 works differently and opens up the possibility of being helped

Existing drugs have a duration of action of maximum 36 hours. According to studies, LIB-01 can have an effect lasting at least seven days

Sexual medicine experts states that there is a great need for new potency drugs

In Sweden only one out of four seeks medical help for erectile dysfunction due to the condition's stigma

IR contact

Elin Trampe CEO

Email: [email protected]
Telephone: +46 72 502 1010